Ascendis Pharma (ASND) Price & Analysis

Compare

640 Followers

ASND Stock Chart & Stats

Day’s Range― - ―

52-Week Range$118.03 - $208.16

Previous CloseN/A

Volume129.18K

Average Volume (3M)498.06K

Market Cap

$11.79B

Enterprise Value$10.78B

Total Cash (Recent Filing)$517.92M

Total Debt (Recent Filing)$847.27M

Price to Earnings (P/E)―

Beta0.80

Next Earnings

Nov 13, 2025

EPS Estimate

-0.32

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.96

Shares Outstanding61,151,463

10 Day Avg. Volume397,923

30 Day Avg. Volume498,057

Financial Highlights & Ratios

PEG Ratio0.86

Price to Book (P/B)-72.81

Price to Sales (P/S)21.17

P/FCF Ratio-25.02

Enterprise Value/Market Cap0.92

Enterprise Value/Revenue34.69

Enterprise Value/Gross Profit40.26

Enterprise Value/Ebitda-63.58

Forecast

1Y Price Target

$250.44

Price Target Upside26.97% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering16

Bulls Say, Bears Say

Bulls Say

Financial PerformanceYorvipath revenues beat company-compiled consensus by about 33%.

Market OpportunityThe inclusion of the Japan market opportunity into the financial model boosts the company's valuation, indicating a strong potential for future revenue.

Regulatory ApprovalThe approval of Yorvipath in Japan highlights its profile as a differentiated treatment for HPT, supporting positive sentiment towards the company's prospects.

Bears Say

Market PenetrationThe company has penetrated less than 5% of the market, suggesting ample room for growth in the US market with an estimated 70K-90K patients.

Sales PerformanceSales of Skytrofa were reported at €50.7M, which was below consensus estimates of €63.2M/€58.9M, suggesting weaker market performance.

Ascendis Pharma News

Ascendis Pharma price target raised to $230 from $227 at BofA

BofA raised the firm’s price target on Ascendis Pharma (ASND) to $230 from $227 and keeps a Buy...

16d ago

ASND

Ascendis Pharma Grants Employee Warrants to Boost Engagement

Ascendis Pharma ( ($ASND) ) has provided an update. On September 9, 2025, Ascendis Pharma’s board of directors...

8d ago

ASND

Ascendis Pharma: Buy Rating Affirmed on Yorvipath Approval and TransCon CNP Prospects

Tazeen Ahmad, an analyst from Bank of America Securities, reiterated the Buy rating on Ascendis Pharma. The associated...

16d ago

ASND

Ascendis Pharma price target raised to $260 from $254 at JPMorgan

JPMorgan raised the firm’s price target on Ascendis Pharma (ASND) to $260 from $254 and keeps an Overweight...

1M ago

ASND

Ascendis Pharma Grants Employee Warrants to Foster Growth

An announcement from Ascendis Pharma ( ($ASND) ) is now available. On August 12, 2025, Ascendis Pharma’s board...

1M ago

ASND

Ascendis Pharma A/S Q2 Earnings Call Highlights Growth

Ascendis Pharma A/S (($ASND)) has held its Q2 earnings call. Read on for the main highlights of the...

1M ago

ASND

UnitedHealth Stock (UNH) Tumbles 50% YTD; Here’s How to Buy the Dip Without the Risk

UnitedHealth Group ($UNH), the largest U.S. health insurer, recently suffered one of its worst stock plunges, down over...

1M ago

ABT

DHR

Ascendis Pharma price target raised to $227 from $194 at TD Cowen

TD Cowen analyst Yaron Werber raised the firm’s price target on Ascendis Pharma (ASND) to $227 from $194...

1M ago

ASND

Ascendis Pharma price target raised to $230 from $210 at RBC Capital

RBC Capital analyst Luca Issi raised the firm’s price target on Ascendis Pharma (ASND) to $230 from $210...

1M ago

ASND

Ascendis Pharma price target raised to $307 from $306 at UBS

UBS raised the firm’s price target on Ascendis Pharma (ASND) to $307 from $306 and keeps a Buy...

1M ago

ASND

Ascendis Pharma price target raised to $290 from $243 at Citi

Citi raised the firm’s price target on Ascendis Pharma (ASND) to $290 from $243 and keeps a Buy...

1M ago

ASND

Ascendis Pharma price target raised to $295 from $289 at Wells Fargo

Wells Fargo raised the firm’s price target on Ascendis Pharma (ASND) to $295 from $289 and keeps an...

1M ago

ASND

Ascendis Pharma’s Promising Growth Trajectory: Buy Rating Affirmed Amid Strong Yorvipath Performance and Strategic Pipeline Developments

Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on Ascendis Pharma yesterday and set a...

1M ago

ASND

Ascendis Pharma Reports Strong Q2 2025 Growth

Ascendis Pharma A/S ( ($ASND) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

ASND

ASND FAQ

What was Ascendis Pharma’s price range in the past 12 months?

Ascendis Pharma lowest stock price was $118.03 and its highest was $208.16 in the past 12 months.

What is Ascendis Pharma’s market cap?

Ascendis Pharma’s market cap is $11.79B.

When is Ascendis Pharma’s upcoming earnings report date?

Ascendis Pharma’s upcoming earnings report date is Nov 13, 2025 which is in 56 days.

How were Ascendis Pharma’s earnings last quarter?

Ascendis Pharma released its earnings results on Aug 07, 2025. The company reported -$0.96 earnings per share for the quarter, beating the consensus estimate of -$1.506 by $0.546.

Is Ascendis Pharma overvalued?

According to Wall Street analysts Ascendis Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ascendis Pharma pay dividends?

Ascendis Pharma does not currently pay dividends.

What is Ascendis Pharma’s EPS estimate?

Ascendis Pharma’s EPS estimate is -0.32.

How many shares outstanding does Ascendis Pharma have?

Ascendis Pharma has 61,151,463 shares outstanding.

What happened to Ascendis Pharma’s price movement after its last earnings report?

Ascendis Pharma reported an EPS of -$0.96 in its last earnings report, beating expectations of -$1.506. Following the earnings report the stock price went up 0.599%.

Which hedge fund is a major shareholder of Ascendis Pharma?

Currently, no hedge funds are holding shares in ASND

Ascendis Pharma Stock Smart Score

Outperform

Fundamentals

Return on Equity

357.68%

Trailing 12-Months

Asset Growth

57.13%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ascendis Pharma

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma (ASND) Earnings & Revenues

Historic Earnings Reports

ASND Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflected a strong performance for Ascendis Pharma with significant revenue growth, successful product launches, and strategic progress in their pipeline. While there are challenges related to currency impacts and patient conversion timelines, these are offset by the momentum in product adoption and regulatory advancements.View all ASND earnings summaries

ASND Stock 12 Month Forecast

Average Price Target

$250.44

▲(26.97% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"124":"$124","170":"$170","216":"$216","262":"$262","308":"$308"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":307,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$307.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":250.44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$250.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":203,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$203.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[124,170,216,262,308],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,199.16,207.45538461538462,215.75076923076924,224.04615384615386,232.34153846153845,240.6369230769231,248.9323076923077,257.22769230769234,265.5230769230769,273.8184615384615,282.11384615384617,290.40923076923076,298.7046153846154,{"y":307,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,199.16,203.10461538461539,207.04923076923077,210.99384615384616,214.93846153846152,218.8830769230769,222.8276923076923,226.7723076923077,230.71692307692308,234.66153846153844,238.60615384615386,242.55076923076922,246.4953846153846,{"y":250.44,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,199.16,199.45538461538462,199.75076923076924,200.04615384615386,200.34153846153845,200.63692307692307,200.9323076923077,201.2276923076923,201.52307692307693,201.81846153846155,202.11384615384614,202.40923076923076,202.70461538461538,{"y":203,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":138.45,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":146.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.51,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.67,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.58,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.48,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":199.16,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >